Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 18, 2018

View Archived Issues

Study identifies new target for combating HSV encephalitis

Gene Therapy Research Institution and Astellas sign option agreement on GT-0001X for ALS

Promising results presented for two next-generation TriKEs in solid tumors

Cannabics reports promising preclinical data on cannabinoid compound in cancer

JCR Pharmaceuticals announces plans to develop JR-441 for MPS IIIA

How to spot a good TB vaccine

Tau leads to clogged pores

Exome-derived circulating RNAs promote pancreatic cancer invasion and metastasis

Meta-analysis links aberrant brain activity to behavioral changes in psychopaths

CL-656 demonstrates promise in melanoma and colon cancer models

First-in-human data for CCR2-targeted PET tracer [64Cu]DOTA-ECL-1i

ALZ-801-derived 3-sulfopropanoic acid prevents Abeta42 oligomerization in Alzheimer's disease

Patient recruitment starts in two phase II trials of DMX-200 in kidney disease

FDA lifts partial clinical hold for XMT-1522

Biogen presents phase II data for BG-00011 in IPF patients

Toll-like receptor 4 antagonists discovered at TaiwanJ Pharmaceuticals

Phenex Pharmaceuticals identifies aryl hydrocarbon receptor antagonists

Galapagos, AbbVie Sarl present mutant CFTR modulators

CRISPR Therapeutics and ViaCyte partner on gene-edited allogeneic stem cell therapies for diabetes

GlaxoSmithKline patents hepatitis B e-antigen and/or surface antigen secretion inhibitors

Pfizer to evaluate Atomwise's platform for drug discovery

LEO Pharma and MorphoSys expand strategic alliance

Aurigene's oral CD47 antagonist AU7R-104 completing IND-enabling studies

European researchers present new data on compounds against Trypanosoma brucei

Sosei suspends HTL-0018318 clinical development following unexpected animal study finding

AmpliPhi Biosciences provides updates regarding the development of its bacteriophage therapeutics

Phase II trial of VK-2809 in patients with NAFLD and elevated LDL-C meets primary endpoint

IMV reports initial data from phase II trial of DPX-Survivac in DLBCL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.